- Release Date: 25/03/25 08:38
- Summary: First patient dosed in phase 3 TACTI-004 lung cancer trial
- Price Sensitive: Yes
- Download Document 273.27KB
- Forums
- ASX - By Stock
- IMM
- Ann: First patient dosed in phase 3 TACTI-004 lung cancer trial
IMM
immutep limited
Add to My Watchlist
1.85%
!
26.5¢

Ann: First patient dosed in phase 3 TACTI-004 lung cancer trial
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
26.5¢ |
Change
-0.005(1.85%) |
Mkt cap ! $388.9M |
Open | High | Low | Value | Volume |
27.5¢ | 27.5¢ | 26.0¢ | $96.84K | 362.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
32 | 381714 | 26.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.5¢ | 110549 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
32 | 381768 | 0.260 |
18 | 670593 | 0.255 |
25 | 530848 | 0.250 |
14 | 311006 | 0.245 |
23 | 4956100 | 0.240 |
Price($) | Vol. | No. |
---|---|---|
0.265 | 110761 | 21 |
0.270 | 77515 | 10 |
0.275 | 167181 | 8 |
0.280 | 183637 | 8 |
0.285 | 126188 | 8 |
Last trade - 13.59pm 01/08/2025 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
AFP
AFT PHARMACEUTICALS LIMITED
Hartley Atkinson, CEO & Founder
Hartley Atkinson
CEO & Founder
SPONSORED BY The Market Online